PriceTargets.com logo

Mainz Biomed - MYNZ Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $14.00
  • Forecasted Upside: 1,096.58%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.17 As of 12/4/2025 05:00 PM ET
▲ +0.01 (0.86%)

This chart shows the closing price for MYNZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mainz Biomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYNZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYNZ

Analyst Price Target is $14.00
▲ +1,096.58% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Mainz Biomed in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 1,096.58% upside from the last price of $1.17.

This chart shows the closing price for MYNZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Mainz Biomed. This rating has held steady since September 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
11/11/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
10/14/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
2/14/2025Maxim GroupInitiated CoverageBuy$14.00
11/25/2024HC WainwrightDowngradeBuy ➝ Neutral
4/12/2024Cantor FitzgeraldReiterated RatingNeutral
3/6/2024HC WainwrightLower TargetBuy ➝ Buy$200.00 ➝ $120.00
11/21/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
11/20/2023HC WainwrightLower TargetBuy ➝ Buy$360.00 ➝ $200.00
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$360.00
9/22/2023HC WainwrightBoost TargetBuy ➝ Buy$280.00 ➝ $360.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$360.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$360.00
8/18/2023HC WainwrightLower TargetBuy ➝ Buy$400.00 ➝ $280.00
5/18/2023Cantor FitzgeraldLower Target$600.00 ➝ $480.00
4/27/2023HC WainwrightLower Target$1,000.00 ➝ $400.00
3/30/2023HC WainwrightReiterated RatingBuy$1,000.00
2/16/2023HC WainwrightReiterated RatingBuy$1,000.00
2/10/2023JonestradingInitiated CoverageBuy$440.00
10/25/2022Cantor FitzgeraldInitiated CoverageOverweight$600.00
6/29/2022HC WainwrightReiterated RatingBuy$1,000.00
6/21/2022HC WainwrightInitiated CoverageBuy$1,000.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/9/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Mainz Biomed logo
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Read More

Today's Range

Now: $1.17
Low: $1.11
High: $1.20

50 Day Range

MA: $1.39
Low: $0.96
High: $1.73

52 Week Range

Now: $1.17
Low: $0.92
High: $8.20

Volume

128,659 shs

Average Volume

928,120 shs

Market Capitalization

$6.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Mainz Biomed?

The following Wall Street sell-side analysts have issued stock ratings on Mainz Biomed in the last year: Maxim Group, and Weiss Ratings.
View the latest analyst ratings for MYNZ.

What is the current price target for Mainz Biomed?

0 Wall Street analysts have set twelve-month price targets for Mainz Biomed in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 1,096.6%. Maxim Group has the highest price target set, predicting MYNZ will reach $14.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $14.00 for Mainz Biomed in the next year.
View the latest price targets for MYNZ.

What is the current consensus analyst rating for Mainz Biomed?

Mainz Biomed currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYNZ, but not buy more shares or sell existing shares.
View the latest ratings for MYNZ.

What other companies compete with Mainz Biomed?

Other companies that are similar to Mainz Biomed include Mana Capital Acquisition, Lixte Biotechnology, Enlivex Therapeutics, Aytu BioPharma and Aptevo Therapeutics. Learn More about companies similar to Mainz Biomed.

How do I contact Mainz Biomed's investor relations team?

The company's listed phone number is 49-6131-554-2860 and its investor relations email address is [email protected]. The official website for Mainz Biomed is mainzbiomed.com. Learn More about contacing Mainz Biomed investor relations.